Selected published studies of chemotherapy/immunochemotherapy regimens with and without radiation treatment in PMBL
| Authors . | Treatment . | Study type . | Patient characteristic . | Outcome . | |
|---|---|---|---|---|---|
| Chemotherapy . | RT+/− . | ||||
| Zinzani et al29 | MACOP-B | Yes | Prospective study, n = 50 | All IPI groups | At 39 months, 93% who achieved complete response were relapse-free; at 8 years, OS was 82% |
| Todeschini et al30 | MACOP-B, VACOP-B or CHOP | Yes | Retrospective study, n = 138 | All IPI groups | At 66 months, EFS was 39% for CHOP and 76% for MACOP-B/VACOP-B |
| Zinzani et al25 | MACOP-B, VACOP-B, ProMACE-CytaBOM, CHOP, or HDS/ABMT | Yes | Retrospective study, n = 426 | All IPI groups | At 10 years, PFS was 35% for CHOP/CHOP-like, 67% for MACOP-B/VACOP-B, and 78% for HDS/ABMT |
| Hamlin et al23 | CHOP/CHOP like, NHL-15, ASCT | No | Retrospective study, n = 141 | All IPI groups | At 11 years, EFS was 34% for CHOP/CHOP-like, 60% for NHL-15, and 60% for ASCT |
| Savage et al24 | CHOP/R-CHOP/MACOP-B/VACOP-B | Variable | Retrospective study, n = 153 | All IPI groups | At 5 years, overall PFS was 69%; only MACOP-B/VACOP-B vs CHOP-like regimens were significantly different |
| Rieger et al33 | CHOP/R-CHOP | Variable: RT intended in 87% | Retrospective analysis, n = 87 | Confined to AA-IPI of 0-1 | At 3 years, EFS was 78% for R-CHOP and 52% for CHOP |
| Soumerai et al37 | R-CHOP | Yes: 77% of responding patients | Retrospective study, n = 63 | All IPI groups | At 5 years, PFS was 68% |
| Dunleavy et al34 | DA-EPOCH-R | No | Prospective study, n = 51 | All IPI groups | At 5 years, EFS was 93% |
| Woessmann et al41 | DA-EPOCH-R | No | Ongoing case series, n = 15 | All IPI groups, age younger than 18 years | At 19 months, EFS was 92% |
| Martelli et al36 | R-MACOP-B, R-VACOP-B, R-CHOP | Yes | Prospective study, n = 125 | All IPI | Estimated 5-year PFS is 86% |
| Authors . | Treatment . | Study type . | Patient characteristic . | Outcome . | |
|---|---|---|---|---|---|
| Chemotherapy . | RT+/− . | ||||
| Zinzani et al29 | MACOP-B | Yes | Prospective study, n = 50 | All IPI groups | At 39 months, 93% who achieved complete response were relapse-free; at 8 years, OS was 82% |
| Todeschini et al30 | MACOP-B, VACOP-B or CHOP | Yes | Retrospective study, n = 138 | All IPI groups | At 66 months, EFS was 39% for CHOP and 76% for MACOP-B/VACOP-B |
| Zinzani et al25 | MACOP-B, VACOP-B, ProMACE-CytaBOM, CHOP, or HDS/ABMT | Yes | Retrospective study, n = 426 | All IPI groups | At 10 years, PFS was 35% for CHOP/CHOP-like, 67% for MACOP-B/VACOP-B, and 78% for HDS/ABMT |
| Hamlin et al23 | CHOP/CHOP like, NHL-15, ASCT | No | Retrospective study, n = 141 | All IPI groups | At 11 years, EFS was 34% for CHOP/CHOP-like, 60% for NHL-15, and 60% for ASCT |
| Savage et al24 | CHOP/R-CHOP/MACOP-B/VACOP-B | Variable | Retrospective study, n = 153 | All IPI groups | At 5 years, overall PFS was 69%; only MACOP-B/VACOP-B vs CHOP-like regimens were significantly different |
| Rieger et al33 | CHOP/R-CHOP | Variable: RT intended in 87% | Retrospective analysis, n = 87 | Confined to AA-IPI of 0-1 | At 3 years, EFS was 78% for R-CHOP and 52% for CHOP |
| Soumerai et al37 | R-CHOP | Yes: 77% of responding patients | Retrospective study, n = 63 | All IPI groups | At 5 years, PFS was 68% |
| Dunleavy et al34 | DA-EPOCH-R | No | Prospective study, n = 51 | All IPI groups | At 5 years, EFS was 93% |
| Woessmann et al41 | DA-EPOCH-R | No | Ongoing case series, n = 15 | All IPI groups, age younger than 18 years | At 19 months, EFS was 92% |
| Martelli et al36 | R-MACOP-B, R-VACOP-B, R-CHOP | Yes | Prospective study, n = 125 | All IPI | Estimated 5-year PFS is 86% |
AA, age-adjusted; ASCT, autologous stem cell transplantation; HDS/ABMT, high-dose sequential chemotherapy and autologous bone marrow transplantation; NHL, non-Hodgkin lymphoma.